 For instance, lung cancer cells can have over 1000 times more procaspase-3 than normal cells.Therefore, by controlling the dosage, one can achieve selectivity between normal and cancerous cells.In addition to its stand-alone activity, PAC-1 has also been shown to markedly synergize with a variety of approved cancer drugs, for example with BRAF and MEK inhibitors in mouse models of melanoma, and with conventional chemotherapeutic agents such as doxorubicin in pet dogs with spontaneous cancers including lymphoma and metastatic osteosarcoma, and with temozolomide in pet dogs with naturally occurring glioma.